Table 2.
Clinical trials combining CDK4/6 inhibitors with immune checkpoint inhibitors.
| DDR targeting agents | Combined immune checkpoint inhibitors | Trial registration number | Disease | Phase | Enrollment |
|---|---|---|---|---|---|
| abemaciclib | nivolumab | NCT03655444 | HNSCC | 1/2 | 32 |
| pembrolizumab | NCT02079636 | NSCLC | 1 | 150 | |
| pembrolizumab | NCT02779751 | NSCLC/ breast cancer |
1 | 100 | |
| pembrolizumab | NCT03997448 | GEA | 2 | 34 | |
| nivolumab | NCT03781960 | Liver cancer | |||
| palbociclib | pembrolizumab | NCT02778685 | Breast cancer | 2 | 22 |
| Avelumab (+Fulvestrant) | NCT03147287 | 2 | 220 | ||
| Avelumab (+Tamoxifen) | NCT03573648 | 2 | 40 | ||
| trilaciclib | atezolizumab | NCT03041311 | SCLC | 2 | 105 |
| Dinacidib | Pembrolizumab | NCT01676753 | Breast cancer | 1 | 32 |
CDK, cyclin-dependent kinase; DDR, DNA damage repair; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; HNSCC, head and neck squamous cell carcinoma; GEA, gastro-esophageal adenocarcinoma.